Dr. John Cush RheumNow
2 years 10 months ago
#ACR23 Abst#1629 from FORWARD registry showed RA pts (n667) with LONG COVID (15%) had worse RA pre-COVID and post-infx, and had worse COVID (more ABx & hospitalization). RA-long Covid pts had 3fold more fibromyalgia (13 vs 41%) https://t.co/VFNAnSxNzN https://t.co/WLqmdM3Nn2
Dr. John Cush RheumNow
2 years 10 months ago
Watch: No Increased Mortality in Patients with RA Receiving Checkpoint Inhibitors
Dr. Mike Putman discusses abstract 1071 with Dr. Madeline O'Sullivan at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/YdIlhLf5gh https://t.co/6dfWHakboh
Dr. John Cush RheumNow
2 years 10 months ago
ACR Daily Recap - MONDAY
Panelists: Drs. Kathryn Dao, Michael Putman and Eric Dein
Moderator: Dr. Jack Cush
https://t.co/b1k1gsHI2z https://t.co/BWu7GXFxhj
Dr. John Cush RheumNow
2 years 10 months ago
IgG4 disease- the WInS withdrawal study results
https://t.co/rg0YJ0LlZM https://t.co/L6SzcD7QlJ
It has been just over a decade since the approval of tofacitinib (JAK1/JAK3-inhibitor) by the US FDA for the treatment of rheumatoid arthritis. Since then, baricitinib (JAK1/JAK2-i), filgotinib and upadacitinib (both selectively targeting JAK1) also have been licensed for the treatment of rheumatoid arthritis. As there are many more JAK-inhibitors evaluated in clinical trials currently, how do you stand out?
Dr. John Cush RheumNow
2 years 10 months ago
Theres a ustekinumab biosimilar, CT-P43 - In a multinational, phase III study in 509 plaque psoriasis pts, CT-P43 was equivalent to the originator, Stelara, with week 16 PASI75 scores of 78% vs 76%, and continued efficacy out to week 40 https://t.co/dEImEp8l90 https://t.co/UoqGgaad8H
Dr. John Cush RheumNow
2 years 10 months ago
FDA issued a safety alert for BCMA- or CD19- Autologous CAR-T cell Immunotherapies; they've received reports & are investigating Risk of T-cell Malignancy (CAR-positive lymphoma) occuring in several products w/in this class (most for Cancer use) https://t.co/RpBhcGarGy https://t.co/mDuXmVW4Fz
You know this; you've taught this; but here's a good study documenting a higher risk of methotrexate toxicity when used in the setting of older patients with chronic kidney disease.
Yesterday's JAMA published a higher 90-day risk of serious adverse events in older adults with CKD taking low-dose methotrexate, compared to hydroxychloroquine.
Dr. John Cush RheumNow
2 years 10 months ago
Rheumatoid Arthritis Topic Podcast
https://t.co/ClEuz2bVzA https://t.co/19jZhSt3Dc
Dr. John Cush RheumNow
2 years 10 months ago
Does GnRHa Reduce Premature Ovarian Insufficiency in SLE Patients on Cyclophosphamide?
https://t.co/GVk2KLoGYq https://t.co/Hv9Bcn8cLg
Dr. John Cush RheumNow
2 years 10 months ago
Why are older RA patients getting mistreated?
Most rheums would say that every RA patient should be started on a DMARD. So I'm shocked that, in a US Medicare 20% sample dataset b/w 2008-17, less than 30% of new RA patients aged 66+ have a DMARD initiated.
https://t.co/VFp3oz8wGK https://t.co/60Jn6ShmDs
Dr. John Cush RheumNow
2 years 10 months ago
Do We Stop or Continue Treatment?
Remission had been a dream, an elusive concept. But then, with the introduction of biologics, conventional synthetic and targeted synthetic DMARDS, patients are able to live longer and with a better quality of life.
https://t.co/qSgfuDvAQb https://t.co/eUzIaC35tl
Dr. John Cush RheumNow
2 years 10 months ago
WATCH: TMP SMX Prophylaxis in GPA
https://t.co/JtIjgxwrCf https://t.co/Tmzdu00oyH
Dr. John Cush RheumNow
2 years 10 months ago
The SMART Study: Split Dose Oral Methotrexate
Dr. Jack Cush discusses abstract 1583 presented at the 2023 ACR Convergence meeting in San Diego.
https://t.co/Blg4EUe5rX https://t.co/0svgLAZ1as
